Shares of Shilpa Medicare tumbled 12 per cent to Rs 480 on the BSE on Monday after the US health regulator issued a warning letter to the company’s Jadcherla formulations facility in Telangana.
“The company has received a warning letter on 9th October 2020 through email from the United States Food and Drug Administration (USFDA) for its Jadcherla facility, Telangana,” Shilpa Medicare said in exchange filing on Saturday, October 10, 2020.
However, the Company said it believes that the warning letter will have minimum impact of disruption of supplies and the existing revenues from operations of this facility.